Children with MOG-IgG positive bilateral optic neuritis misdiagnosed as fulminant idiopathic intracranial hypertension
- PMID: 39675122
- DOI: 10.1016/j.msard.2024.106205
Children with MOG-IgG positive bilateral optic neuritis misdiagnosed as fulminant idiopathic intracranial hypertension
Abstract
Background: Fulminant idiopathic intracranial hypertension (IIH) is characterized by headache, rapid decrease of vision and elevated CSF-opening pressure.
Objective: To delineate a subgroup of MOGAD mimicking fulminant IIH.
Methods: In this case series children with MOGAD with vision loss, optic disc swelling and elevated CSF opening pressure, initially diagnosed with fulminant IIH, were included.
Results: 8 MOGAD patients (median age 12.5y, f:m = 7:1) with an initial diagnosis of fulminant IIH were included. Rapid bilateral visual loss and headache was present in all patients in addition to bilateral optic disc swelling and decreased visual acuity. In 2 patients cMRI showed prominent optic discs or an empty sella sign. In 7 patients the CSF opening pressure was markedly elevated. Patients were treated with Acetazolamide (n = 6), CSF external drainage (n = 2) or implantation of VP shunt (n = 1). Intravenous Methylprednisolone was administered in all patients because of worsening of symptoms, positive MOG-ab titers and/or new MRI white matter lesions. Visual recovery was good with residuals in 1/8 children. OCT revealed thickening of pRNFL in the acute stage in all patients with a rapid declining of pRNFL and retinal atrophy thereafter.
Conclusion: Children with bilateral MOGAD-ON presenting with loss of vision and elevated CSF opening pressure are at risk of being misdiagnosed as fulminant IIH. The role of elevated CSF opening pressure in MOGAD warrants further investigations. We recommend to include measurement of CSF opening pressure in the work up of neuroinflammatory diseases, in particular in patients with suspected MOGAD, to consider adapted pressure management.
Keywords: Acquired demyelinating syndrome; Bilateral on; Children; Idiopathic intracranial hypertension; Mogad.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest • EM.W. has received travel grants from UCB • D.T. has nothing to declare. • N.B. has nothing to declare. • A.B. has received travel support: Octapharma; honorary für advisory board: Horizon • A.P. has nothing to declare. • P.C, has received research support by Roche/Genentech, Novartis, Apellis Phamaceuticals, Katairo GmbH • T.G. has nothing to declare. • E.K. has nothing to declare. • M.N. has nothing to declare. • M.No. has nothing to declare. • S.S. has nothing to declare. • JC.SB. has nothing to declare. • D.Y. has nothing to declare. • M.R. has received research support by Roche Austria (Vascage subproject B.9): Biomarkers of neuroinflammation, Austrian Science Funds (FWF) (P32699): Epitope specificity of MOG antibodies (governmental), Austrian Research Promotion Agency (FFG) (Vascage subproject B.9): Biomarkers of neuroinflammation (governmental). • T.P. has nothing to declare. • I.A. has received travel grants from Alexion, BMS, Biogen Idec and Guthy-Jackson Charitable Foundation, served on scientific advisory boards for Merck, Roche, Alexion, Horizon, Sanofi and received research support from Diamed, none related to this study • K.R. has received research support by Consultant Operetta 2 Study, Roche, honoraria for talks from UCB, Horizon
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
